Circulating Long Noncoding RNA as a Potential Target for Prostate Cancer

Su, Yuxin; Yu, Jin; Huang, Yaqin; Yang, Jin

doi:10.3390/ijms160613322

Cited by 40 publications

(27 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have demonstrated that circulating lncRNAs could forecast prognosis and predict therapeutic efficacy in different kinds of cancers [41,42,43]. For example, three circulating lncRNAs (LincRNA-p21, GAS 5, HOTAIR) have been discovered as biomarkers to predict chemoradiotherapy sensitivity in head and neck cancers including nasopharyngeal carcinoma [44], indicating the important value of circulating lncRNAs in clinical outcome predictions.…”

Section: Discussionmentioning

confidence: 99%

Microarray Expression Profiling of Long Non-Coding RNAs Involved in Nasopharyngeal Carcinoma Metastasis

Wen

Tang

et al. 2016

IJMS

View full text Add to dashboard Cite

Increasing evidence has demonstrated a significant role for long non-coding RNAs (lncRNAs) in tumorigenesis. However, their functions in nasopharyngeal carcinoma (NPC) metastasis remain largely unknown. In this study, a model comparing high and low metastatic NPC cell lines (5-8F vs. 6-10B and S18 vs. S26) was constructed to determine the expression profile of lncRNAs using the microarray analysis, and we found 167 lncRNAs and 209 mRNAs were differentially expressed. Bioinformatic analysis indicated that the dysregulated mRNAs participated in important biological regulatory functions in NPC. Validation of 26 significantly dysregulated lncRNAs by qRT-PCR showed the expression patterns of 22 lncRNAs were in accordance with the microarray data. Furthermore, the expression level of ENST00000470135, which was the most upregulated lncRNA in high metastatic cell lines, was significantly higher in NPC cell lines and tissues with lymph node metastasis (LNM) and knocking down ENST00000470135 suppressed the migration, invasion and proliferation of NPC cells in vitro. In conclusion, our study revealed expression patterns of lncRNAs in NPC metastasis. The dysregulated lncRNAs may act as novel biomarkers and therapeutic targets for NPC.

show abstract

Section: Discussionmentioning

confidence: 99%

Microarray Expression Profiling of Long Non-Coding RNAs Involved in Nasopharyngeal Carcinoma Metastasis

Wen

Tang

et al. 2016

IJMS

View full text Add to dashboard Cite

show abstract

“…AP001189.4 is an antisense long non‐coding RNA (lncRNA) gene with unknown function (Flicek et al, ) (http://www.ensembl.org). Interestingly, changes in lncRNA expressions are detected in the serum and urine of cancer patients as well as in circulating tumor cells and in various stages of PrCa tumors, and these changes might be used as biomarkers for cancer detection (Su et al, ).…”

Section: Discussionmentioning

confidence: 99%

Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene

Nurminen

Rantapero

Wong

et al. 2016

Genes Chromosomes & Cancer

View full text Add to dashboard Cite

A total of nine non-coding variants on 11q13.5 predispose men to prostate cancer (PrCa). rs200331695 within the EMSY intron is associated with aggressive PrCa and two high linkage disequilibrium (LD) groups of single-nucleotide polymorphisms (SNPs) in the intergenic region are associated with PrCa death. Here, the cis-effect of the SNPs on gene expression using expression quantitative trait loci analysis was investigated. The regulatory potential was screened in prostate tumors (n = 41) and in whole blood (n = 99). The results were validated in a second tumor set (n = 41), in lymphoblastoid cell lines (LCLs) (n = 38), and using the GTEx Portal. The effects of haplotypes were analyzed in the whole blood. The high LD SNPs (rs143975731, rs12277366, rs2155225, and rs2155222) were associated with DGAT2 expression in both tumors sets (screening P = 0.035-0.043; validation P = 0.005-0.018). The PrCa death-associated alleles decreased the expression by two-fold. rs200331695 decreased DGAT2 expression in LCLs (P = 0.006). The findings of SNPs regulating CAPN5 (P = 0.026-0.046) and AP001189.4 (P = 0.03-0.039) in the whole blood were not observed in LCLs, but the association with AP001189.4 expression was validated via the GTEx Portal (P = 8.7 × 10(-5) to 4.3 × 10(-4) ), which suggests that the high LD intergenic SNPs exert a tissue-dependent effect on the expression of two genes. No haplotypes including the risk SNPs at 11q13.5 were associated with gene expression and PrCa. The findings indicate the functionality of the PrCa death-predisposing SNPs rs143975731, rs12277366, rs2155225, and rs2155222 as DGAT2 regulators in prostate tumors. © 2016 Wiley Periodicals, Inc.

show abstract

“…Prostate cancer-associated transcript 1 (PCAT1) gene is located on human chromosome 8q24, approximately 725 KB upstream the c-MYC oncogene. This locus is linked with prostate cancer risk and susceptibility [Ge et al, 2013;Su et al, 2015]. This lncRNA is mainly cytoplasmic,though, in minor proportion can be found in the nucleus.…”

Section: Pcat1mentioning

confidence: 99%

Multiple Functions of Long Non‐Coding RNAs in Oxidative Stress, DNA Damage Response and Cancer Progression

Tehrani

Karimian

Parsian

et al. 2017

J of Cellular Biochemistry

View full text Add to dashboard Cite

In addition to aberrant alternation of transcriptome, it is now suggested that dysregulation of the non-coding transcripts, particularly long non-coding RNAs (lncRNAs), which comprise the majority of the genome, is contributed to cancer initiation and progression. As the result of recent huge efforts, the possible roles of numerous lncRNAs in the human cancers were characterized, as well as various strategies with inhibitory effects to target these transcripts on the transformed cells. Moreover, DNA damage response (DDR) pathway is a complex regulatory network responsible for the identification of disruptions in DNA structure, integrity and stability-it is reported to be associated with the upregulation and down-regulation of lncRNAs. This review explores the involvement of the various lncRNAs in different human cancers, afterwards discusses the association of the lncRNAs expression with the DDR and oxidative stress, which are implicated in a myriad pathophysiological and physiological intra-and extracellular damages.

show abstract

Circulating Long Noncoding RNA as a Potential Target for Prostate Cancer

Cited by 40 publications

References 67 publications

Microarray Expression Profiling of Long Non-Coding RNAs Involved in Nasopharyngeal Carcinoma Metastasis

Microarray Expression Profiling of Long Non-Coding RNAs Involved in Nasopharyngeal Carcinoma Metastasis

Expressional profiling of prostate cancer risk SNPs at 11q13.5 identifies DGAT2 as a new target gene

Multiple Functions of Long Non‐Coding RNAs in Oxidative Stress, DNA Damage Response and Cancer Progression

Contact Info

Product

Resources

About